Last reviewed · How we verify
IV Casopitant (GW679769)
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | IV Casopitant (GW679769) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Casopitant selectively antagonizes the NK1 receptor, which is a key mediator of nausea and vomiting pathways in the central nervous system. By blocking substance P binding to NK1 receptors, it prevents both acute and delayed emetic responses triggered by chemotherapy. This mechanism complements 5-HT3 antagonists and corticosteroids in multimodal antiemetic regimens.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Dizziness
- Fatigue
Key clinical trials
- A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. (PHASE3)
- Cyclophosphamide Drug Interaction Study In Cancer Patients (PHASE1)
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults (PHASE1)
- A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (PHASE3)
- A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (PHASE3)
- Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Casopitant (GW679769) CI brief — competitive landscape report
- IV Casopitant (GW679769) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI